The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Perspective
Volume 356:2341-2343 June 7, 2007 Number 23
NextNext

The Stem-Cell Market — Patents and the Pursuit of Scientific Progress
Fiona Murray, Ph.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
University of Wisconsin researcher James Thomson and his colleagues wowed the scientific community when they reported in November 1998 that they had isolated and cultured human embryonic stem cells.1 They also precipitated intense debate. Although moral dilemmas and federal funding of stem-cell research have received the most media attention, behind-the-scenes concern has centered on the market for stem cells — the ownership, control, pricing, and availability of stem-cell lines. For many academic researchers hoping to build on Thomson's discovery, the difficulty of obtaining stem cells was immensely frustrating.

This difficulty arose because not only did Wisconsin have material rights to . . . [Full Text of this Article]


Source Information

Dr. Murray is an associate professor of management at the Sloan School of Management, Massachusetts Institute of Technology, Cambridge.



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.